Protocol Ledger

NCT06179875 · Phase III · COMPLETED

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

Interventional Phase III clinical trial protocol NCT06179875 sponsored by Viridian Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-31 Enrollment: 139 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06179875
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)139 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06179875
Protocol FieldVerified Registry Value
NCT IdentifierNCT06179875
Consolidated Lead SponsorViridian Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment139 participants (ACTUAL)
Registered Start Date2024-01-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06179875
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI